tiprankstipranks
Trending News
More News >

Shandong Xinhua Pharmaceutical Reports Q1 2025 Financial Results

Story Highlights
Shandong Xinhua Pharmaceutical Reports Q1 2025 Financial Results

Don’t Miss TipRanks’ Half-Year Sale

Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has issued an update.

Shandong Xinhua Pharmaceutical Company Limited has released its unaudited financial results for the first quarter of 2025, showing a slight decrease in operating income by 1.81% compared to the same period last year. The company reported a significant decline in net profit attributable to shareholders, down by 20.99%, and a substantial drop in net cash flow from operating activities by 77.87%. Despite these challenges, the company’s total assets increased by 2.77%, and net assets attributable to shareholders rose by 3.28%, indicating a stable asset base.

More about Shandong Xinhua Pharmaceutical Company Limited Class H

Shandong Xinhua Pharmaceutical Company Limited is a joint stock company based in China, primarily engaged in the pharmaceutical industry. The company focuses on the production and distribution of pharmaceutical products and related services.

YTD Price Performance: -3.10%

Average Trading Volume: 2,170,030

Technical Sentiment Signal: Sell

Current Market Cap: HK$8.56B

See more data about 0719 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1